GlobeNewswire

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
10/11/2026
94% of participants maintained seroresponse five years after a single vaccination Comparable antibody persistence observed in older (65+) and younger adults Data further reinforce IXCHIQ ® 's differentiated profile with [...]
Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®
10/11/2026
94% des participants ont maintenu une séroréponse cinq ans après une dose unique du vaccin La persistance des anticorps chez les adultes âgés de 65 ans et plus est comparable à celle des jeunes adultes Ces données [...]
Australian therapy aimed at halting MND progression and restoring function advances to national Phase 2 trial
10/11/2026
Video interviews, overlay and photos here BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- An Australian-developed therapy aimed at halting the progression of motor neurone disease (MND) and restoring function by [...]
Stryker announces intention to nominate Jim Davis to board of directors
09/11/2026
Portage, MI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Stryker announces intention to nominate Jim Davis to board of directors Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis for election to the [...]
PetMeds Announces Strategic Partnership with Pet Supermarket to Expand Pharmacy Offering Across Retail and Digital Channels
09/11/2026
DELRAY BEACH, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced a new partnership with Pet Supermarket to offer pet prescription [...]
Apollomics Reports First-Half 2026 Financial Results
09/11/2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026 ( [...]
ImageneBio Reports Third Quarter 2026 Financial Results
09/11/2026
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended September 30, 2026, and provided a company update. Company [...]
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
09/11/2026
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough [...]
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
09/11/2026
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last [...]
Globus Medical to Participate in Jefferies Global Healthcare Conference
09/11/2026
AUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Jefferies Global Healthcare [...]
Harrow Announces Third Quarter 2026 Financial Results
09/11/2026
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026
09/11/2026
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA [...]
Xenon Reports Q3 2026 Financial Results and Provides Business Update
09/11/2026
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies [...]
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
09/11/2026
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
09/11/2026
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track [...]
SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.
09/11/2026
Concludes 30-Year Tenure Leading Development of TPOXX®, the First FDA-Approved Antiviral for the Treatment of Smallpox NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies (NASDAQ: SIGA), a commercial stage [...]
IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
09/11/2026
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious [...]
Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures
09/11/2026
The Board approved plan target s a 25%–30% reduction in annualized operating expenses, compared to annualized 2026 GAAP and non-GAAP operating expenses, once fully implemented, expected by the end of Q 1 202 7 Cost [...]
Five Vital Nutrients Bestsellers Earn TESTED by SuppCo Certification Verifying Label Claims
09/11/2026
MIDDLETOWN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vital Nutrients , a practitioner-founded nutritional supplement company, today announced that five of its dietary supplements have earned TESTED by SuppCo [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum